Heart health app updated
A new version of the free MyHeart Counts app is available. It now features graphical feedback, interventions and coaching.
Gene activity foretells autoimmune disease
Stanford researchers and their collaborators have found a way to tell whether patients with systemic sclerosis were improving during drug treatment a year before a standard clinical test could.
Benefit shown in a subgroup of patients
Glioblastoma patients with a high degree of vascularization of their tumors were found to have benefited from a treatment previously deemed ineffective, a new Stanford study shows.
Podcast: Cleaning up sports
In this podcast, anti-doping chief Travis Tygart discusses some of the major lessons learned from the Rio Olympics about global anti-doping efforts.
Seizure ‘choke point’ in brain
Stanford researchers used a rodent model to discover that shifting the firing pattern of a particular set of brain cells is all it takes to initiate, or to terminate, an absence seizure.
Smartphones’ potential for medical research
Stanford researchers say that data collected through MyHeart Counts, a heart-health study in which participants transmit information through an app, demonstrates the potential of smartphones to transform the measurement of physical activity and fitness for clinical research.
Blood test to evaluate lung cancer tumors
A technique developed at Stanford for detecting the genetic profiles of tumor cells sifted from the bloodstream could offer a valuable tool for the clinic and the lab.
Drug interactions that may reduce mortality
Stanford researchers found that certain drug combinations were associated with lower mortality rates among breast cancer patients, pointing to potential drug targets and new ways of thinking about known diseases.
Measuring electrical stimulation of brain tissue
Until now, no quantitative relationship between the level of electricity applied to the brain and the extent of neural activity generated has been plotted in humans.
Child’s life saved by experimental drug
Four-year-old Zoe Harting is doing well after participating in a phase-2 clinical trial of the first drug for a deadly genetic disease, spinal muscular atrophy type 1.
Leading in Precision Health
Stanford Medicine is leading the biomedical revolution in precision health, defining and developing the next generation of care that is proactive, predictive and precise.
A Legacy of Innovation
Stanford Medicine's unrivaled atmosphere of breakthrough thinking and interdisciplinary collaboration has fueled a long history of achievements.